PTO/SB/08 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OND CONTROL HOLLINGS.						
	Substitute for fo	rm 14	49/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: November 18, 2009				Application Number	10/500,296	
				Filing Date	1/6/2003	-
				First Named Inventor	Yuji YAMAZAKI	
				Art Unit	1644	
	(use as many shee	ets as	necessary)	Examiner Name	Zachary S. Skelding	-
Sheet	1	of	1	Attorney Docket Number	081356-0218	7

U.S. PATENT DOCUMENTS						
Examin er Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
						_

		NON PATENT LITERATURE DOCUMENTS	
Initials* No.1 item (book, magazine		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, megazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	D1	Japanese Office Action 2003-5580417 dated August 20, 2009.	No
	D2	Yukihiro HASEGAWA et al., "VITAMIN D-RESISTANT HYPOPHOSPHATEMIC RICKETS", THE BONE, Vol. 15, No. 6, November 2001, pp. 1-9.	Yes
	D3	Ann E. BOWE et al., "FGF-23 Inhibits Renal Tubular Phosphate Transport and Is a PHEX Substrate", Biochemical and Biophysical Research Communications 284, 977—981 (2001).	

_		
Examiner Signature	Date Considered	

EXAMPET: Initial if reference considered, whether or not claston is in conformance with MEPF 4/3 Draw fine through classion if not in conformance and not considered, include copy of this form with next communications to significant. I Applicant is value; cations of designation remarks (optional, 2 See Kinds Cycles of USPTO Patient Documents as www.uspto.gov or MEPF 9/01 04. 3 Erise Office that issued the occument, by the sub-civilence colorwards, because of the conformation of the conformation of the pair of the Emperor must percende the seater another of the patient of the pair of the Emperor must percende the seater another of the patient of the conformation seater of the part of the Emperor must percende the seater another of the patient documents. Which documents were considered on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is stationary.

This collection of Information is required by 37 CRF, 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USFTO opposes an application. Confidentially is governed by \$5 U.S.C. 122 and 37 CFF.11.14. The collection is estimated to size 2 hours compiled including gathering, preparing, and submitting the completed application from to the USFTO. Time will vary depending upon the individual case. Any comments on the amount of time pour sequite to complete this form and/or suggestions for residency fine burstein, should be sent to the Chile Information Offices. Any comments on the amount of time pour sequite to complete this form and/or suggestions for residenting this burstein, should be sent to the Chile Information Offices. Any Comments of the Chile Patents, P.O. Box 1456, Mexandria, Vx 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1456, Mexandria, Vx 22313-1450.